Brain Stimulation and Better Sleep: Two Emerging Breakthroughs Reshaping Addiction Recovery

Two innovative approaches are changing how doctors treat addiction: brain stimulation techniques that reduce cravings by targeting damaged brain circuits, and a sleep medication that addresses one of recovery's most overlooked relapse triggers. These aren't replacements for existing treatments like medication or therapy, but rather tools that work alongside them to address the neurological roots of substance use disorders that conventional approaches often miss.

Why Brain Stimulation Is Gaining Traction in Addiction Treatment

The numbers tell a sobering story. Approximately 48.4 million people in the United States received a substance use disorder diagnosis in 2024, and up to 75 percent relapse within the first weeks after leaving a 28-day residential treatment program. For substances like methamphetamine and cocaine, no approved medication treatments currently exist. This gap is where brain stimulation enters the picture.

Two main brain stimulation approaches are showing promise. Transcranial magnetic stimulation (TMS) uses magnetic pulses to alter activity in brain networks linked to mood, impulse control, and craving. Focused ultrasound goes deeper, targeting the nucleus accumbens—a small structure at the heart of the brain's reward system that drives compulsive drug-seeking behavior.

"Brain stimulation is not a cure," explains Dr. Diana M. Martinez, Professor of Psychiatry at Columbia University Irving Medical Centre. "It works alongside existing treatments, whether medication or behavioral therapy, to reduce the cravings and emotional distress that so often derail recovery."

How Transcranial Magnetic Stimulation Works for Different Substances

TMS received FDA approval for depression in 2008 and has since been cleared for obsessive-compulsive disorder and smoking cessation. For depression and OCD, roughly one-third of patients reach full remission, and between 50 and 60 percent show meaningful clinical improvement. The effects typically last around six months, and clinicians can use booster sessions to extend those benefits.

For specific substance use disorders, the research shows varied but encouraging results:

• Smoking Cessation: A pivotal 2021 multicenter trial found that between 17 and 27 percent of participants stopped smoking with TMS alone. When combined with varenicline (a prescription quit-smoking medication), quit rates jumped to 60 to 80 percent, suggesting real potential in combination approaches.
• Alcohol Use Disorder: A 2023 meta-analysis in Neuropsychopharmacology found that multiple brain stimulation sessions reduced both alcohol craving and actual consumption. Single sessions made no difference, indicating that repeated treatment is necessary.
• Opioid Use Disorder: Four randomized controlled trials all showed that TMS reduces craving compared to sham treatment. Two of those studies also found significant reductions in depressive symptoms, which matters greatly given how often depression and addiction occur together.
• Cocaine and Methamphetamine: Researchers have conducted more than 20 studies on cocaine use disorder, with many showing reductions in craving and use. Four randomized controlled trials on methamphetamine use disorder show improved craving after multiple TMS sessions.

Focused Ultrasound: Targeting the Brain's Reward Center More Precisely

While TMS reaches the outer regions of the brain, focused ultrasound penetrates deeper to target the nucleus accumbens—the central hub of the brain's reward circuitry. Dr. James J. Mahoney, Associate Professor and Clinical Neuropsychologist at the University of Virginia School of Medicine, leads research using this approach. The procedure uses a helmet fitted with thousands of ultrasound transducers that converge energy on one precise target, with an MRI scanner monitoring the procedure throughout.

In a 16-person open-label trial, researchers recruited participants from a residential 28-day treatment program in Morgantown, West Virginia. All were already on medication for opioid use disorder. The results were striking: cue-induced craving ratings fell sharply after the brain stimulation procedure and stayed low throughout a 90-day follow-up period.

What made this finding particularly significant was that the craving reductions weren't limited to opioids. Craving scores for methamphetamine, cocaine, benzodiazepines, cannabis, alcohol, and nicotine all dropped substantially after a single session. Urine toxicology results supported this picture—most participants with primary opioid use disorder tested negative for all substances at every follow-up point across 90 days.

Participants also reported improvements across daily life: anxiety fell, focus improved, frustration tolerance increased, and engagement with family, work, and education grew. Importantly, no reductions appeared in naturally rewarding activities such as eating or socializing, which matters because the nucleus accumbens also governs everyday pleasure.

Sleep Medication Addresses a Hidden Relapse Trigger

While brain stimulation tackles cravings directly, another emerging tool addresses one of recovery's most overlooked challenges: sleep disturbance. Up to 80 percent of people with alcohol use disorder experience insomnia during withdrawal, and those difficulties frequently persist well beyond the acute phase. Crucially, researchers have found that the severity of sleep disturbances predicts the likelihood of relapse and later substance use.

Suvorexant, an FDA-approved sleep medication, works differently from traditional sleeping pills. Rather than sedating the brain broadly, it blocks orexin receptors—the brain systems responsible for maintaining active wakefulness. By reducing the "stay awake" signal rather than artificially forcing sedation, suvorexant allows the body to transition into sleep more naturally.

What makes this particularly relevant to addiction medicine is where orexin receptors sit in the brain. These receptors connect directly to the brain's reward and motivation systems—the very circuits that drive craving, drug-seeking behavior, and the emotional turbulence of withdrawal. Blocking orexin signaling may therefore do more than simply improve sleep; it may address some of the neurological underpinnings of addiction itself.

What Clinical Trials Show About Suvorexant in Recovery

A landmark clinical trial published in Science Translational Medicine examined suvorexant in people with opioid use disorder. The randomized, double-blind, placebo-controlled trial enrolled 38 participants, all of whom researchers first stabilized on buprenorphine/naloxone before assigning them to receive suvorexant (20 mg or 40 mg) or a placebo.

The findings stood out across several measures. Sleep improved significantly—participants receiving suvorexant slept for longer than those on placebo, both during the buprenorphine dose-reduction period and during the monitoring period that followed. Withdrawal symptoms eased: after buprenorphine/naloxone ended, the suvorexant group reported lower withdrawal severity compared to those receiving placebo.

Craving-related measures shifted positively. During the dose-reduction phase, those taking suvorexant reported reduced opioid "wanting," a greater desire to avoid opioids, and a stronger sense of self-control over opioid use compared to the placebo group. Benefits continued after the medication phase ended—even after buprenorphine/naloxone ended, participants who had taken suvorexant continued to report a higher desire to avoid opioids relative to the placebo group.

Critically, no significant misuse risk appeared. Participants did not rate suvorexant highly in terms of subjective "high" or "liking," and they assigned it a low estimated street value. Researchers found no evidence of dose-dependent increases in misuse potential, and no serious adverse events occurred during the trial.

How to Integrate These New Tools Into Recovery Plans

• Assess Individual Needs: Brain stimulation and sleep medication work best when matched to a person's specific challenges. Someone struggling primarily with cravings may benefit most from TMS or focused ultrasound, while someone whose relapse risk is driven by insomnia might prioritize suvorexant alongside their existing medication-assisted treatment.
• Combine With Existing Treatments: Neither brain stimulation nor suvorexant replaces medication-assisted treatment, behavioral therapy, or counseling. Instead, they complement these approaches by addressing neurological barriers that traditional treatments alone may not fully resolve.
• Plan for Ongoing Support: Brain stimulation effects typically last around six months, meaning booster sessions may be necessary. Sleep medication should be part of a broader sleep hygiene and recovery plan, not a standalone solution.
• Monitor for Individual Responses: Not everyone responds equally to these treatments. Regular follow-up with clinicians helps determine whether the approach is working and whether adjustments are needed.

What Experts Say About the Future of Addiction Treatment

Dr. Redonna Chandler, Scientific Adviser at the Addiction Policy Forum, stressed the urgent need for new approaches given the persistently high relapse rates following residential treatment. The research community is responding. Researchers are planning a Phase II trial examining suvorexant specifically for people with alcohol use disorder and co-occurring insomnia, citing the unmet clinical need and the theoretical basis for orexin-targeted treatment in this population.

The evidence, while promising, is still developing. The key opioid trial with focused ultrasound enrolled only 16 participants in the main trial, and researchers need larger, more diverse trials to confirm these findings at scale. Studies into suvorexant for sleep disturbance in alcohol use disorder and other substance use disorders remain at an earlier stage. Nevertheless, the direction of travel is encouraging.

For the millions of people worldwide who carry the double burden of addiction and chronic sleep problems, or who struggle with persistent cravings despite conventional treatment, these emerging approaches offer something genuinely new. They represent a shift toward understanding addiction as a neurological condition that sometimes requires neurological solutions—not as a moral failing that willpower alone can overcome.